Fero Industries, Inc. (OTCBB: FROI) (the “Company”) is pleased to provide certain disclosures relating to the ten pending patent applications of Pyro Pharmaceuticals, Inc. As previously announced, the Company has initiated the process of acquiring Pyro Pharmaceuticals, Inc. through an exchange of Pyro’s capital stock for shares of the Company’s common stock, with Fero remaining as the parent entity and Pyro as a subsidiary. The acquisition of Pyro is expected to close by November 30, 2009.
Alan M. Schechter, Chairman and CEO of Pyro Pharmaceuticals, Inc, was quoted as saying, “Pyro looks forward to completing the business combination with Fero Industries and pursuing its strategy of arresting bacterial growth by inhibiting specific metabolic pathways.”
Biochemical pathways govern the synthesis and metabolism of molecules required by all living organisms. Blocking a metabolic pathway by inhibiting one or more enzymes in a pathway can cause deleterious consequences for that organism, or a particular affliction, such as an inborn error in metabolism, or death. The inhibition of a pathway that ultimately results in the death of the organism is, a priori, inhibition of a pathway required for the survival of the organism and is termed an essential pathway. The inhibition of a pathway that does not result in the death of the organism can render that organism avirulent by affecting one or more processes that are required for pathogenesis.